Circular RNA Expression of Peripheral Blood Mononuclear Cells Associated with Risk of Acute Exacerbation in Smoking Chronic Obstructive Pulmonary Disease

DOI: https://doi.org/10.2147/copd.s448759

2024-03-20

International Journal of COPD

Abstract:Xu-Rui Shen, 1, &ast Ying-Ying Liu, 2, &ast Rui-Qi Qian, 1, &ast Wei-Yun Zhang, 2 Jian-An Huang, 1 Xiu-Qin Zhang, 1 Da-Xiong Zeng 2 1 Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Jiangsu, People's Republic of China; 2 Department of Pulmonary and Critical Care Medicine, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiu-Qin Zhang, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, Jiangsu, 215006, People's Republic of China, Tel +86-18912616972, Email Da-Xiong Zeng, Department of Pulmonary and Critical Care Medicine, Suzhou Dushu Lake Hospital, No. 9 Chongwen Road, Suzhou, Jiangsu, 215006, People's Republic of China, Tel +86-15895567963, Email Purpose: Circular RNAs (circRNAs) are newly identified endogenous non-coding RNAs that function as crucial gene modulators in the development of several diseases. By assessing the expression levels of circRNAs in peripheral blood mononuclear cells (PBMCs) from patients with chronic obstructive pulmonary disease (COPD), this study attempted to find new biomarkers for COPD screening. Patients and Methods: We confirmed altered circRNA expression in PBMCs of COPD (n=41) vs controls (n=29). Further analysis focused on the highest and lowest circRNA expression levels. The T -test is used to assess the statistical variances in circRNAs among COPD patients in the smoking and non-smoking cohorts. Additionally, among smokers, the Spearman correlation test assesses the association between circRNAs and clinical indicators. Results: Two circRNAs, hsa_circ_0042590 and hsa_circ_0049875, that were highly upregulated and downregulated in PBMCs from COPD patients were identified and verified. Smokers with COPD had lower hsa_circ_0042590 and higher hsa_circ_0049875, in comparison to non-smokers. There was a significant correlation (r=0.52, P< 0.01) between the number of acute exacerbations (AEs) that smokers with COPD experienced in the previous year and the following year (r=0.67, P< 0.001). Moreover, hsa_circ_0049875 was connected to the quantity of AEs in the year prior (r=0.68, P< 0.0001) as well as the year after (r=0.72, P< 0.0001). AUC: 0.79, 95% CI: 0.1210– 0.3209, P< 0.0001) for hsa_circ_0049875 showed a strong diagnostic value for COPD, according to ROC curve analysis. Hsa_circ_0042590 showed a close second with an AUC of 0.83 and 95% CI: − 0.1972--0.0739 (P < 0.0001). Conclusion: This research identified a strong correlation between smoking and hsa_circ_0049875 and hsa_circ_0042590 in COPD PBMCs. The number of AEs in the preceding and succeeding years was substantially linked with the existence of hsa_circ_0042590 and hsa_circ_0049875 in COPD patients who smoke. Additionally, according to our research, hsa_circ_0049875 and hsa_circ_0042590 may be valuable biomarkers for COPD diagnosis. Keywords: chronic obstructive pulmonary disease, circular RNAs, smoking, acute exacerbation, biomarker Chronic obstructive pulmonary disease (COPD) is mainly manifested as incompletely reversible airflow limitation in the lungs, and the airflow limitation is usually gradual, moreover, its degree is often closely related to the lung's inflammatory response to harmful particles or gases. 1 At present, COPD is a global public health problem. 2 According to a systematic analysis, 391.9 million people worldwide had COPD in 2019 at a prevalence of 10.3% according to the GOLD criteria. 3 COPD-related fatalities accounted for 5.7% of all deaths in 2017. The bulk of COPD cases worldwide are concentrated in China, the nation with the largest population. According to estimates, the prevalence of COPD in China was 13.6%, and in 2016, 4 COPD was the country's fifth most prevalent cause of death. The percentage of COPD patients who have at least one AECOPD episode per year varies from 9.16% to 22.40%. 5 However, most current COPD treatments focus on relieving symptoms and preventing acute exacerbations. Elucidating the pathophysiology of COPD is crucial in developing targeted interventions for respiratory diseases. In recent years, the research of non-coding ribonucleic acid (ncRNA) in the field of disease pathogenesis has been heating up, and the research content has become more and more in-depth. Among the various types of non-coding RNA, circRNA has emerged as a particularly noteworthy focus in current research into the molecular mechanisms of diseases due to its distin -Abstract Truncated-

respiratory system